866-997-4948(US-Canada Toll Free)

Non-alcoholic Steatohepatitis (NASH) Biomarkers Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Published By :

Transparency Market Research

Published Date : Jan 2017

Category :

Pharmaceutical

No. of Pages : 152 Pages

Global Non-alcoholic Steatohepatitis Biomarker Market: Overview

Non-alcoholic steatohepatitis (NASH) is liver disease which is categorized under the spectrum of non-alcoholic fatty liver disease (NAFLD). NASH is an advanced form of NAFLD where the liver inflammation occurs owing to fat deposition in liver. The fat accumulation may be induced by genetic abnormalities, metabolic dysfunction, drug induced damages, etc. Untreated and advanced NASH is one of the major reason for liver cirrhosis and sever liver damage such as liver failure. Presently three distinct method are used for diagnosis and monitoring of NASH, those are biopsy derived histopathology, imaging tools like transient elastography (TE), magnetic resonance imaging (MRI), etc., and in vitro diagnostic using biomarkers. As per the World Gastroenterology Organization It is estimated that around 20% to 30% of world population is affected with NAFLD.

Global Non-alcoholic Steatohepatitis Biomarker Market: Drivers and Trends

Increasing prevalence of NASH associated conditions like obesity and diabetes are expected to drive the growth of NASH biomarkers market. According to Deutsche Bank around 45 million people are anticipated to be affected by NASH in the U.S. and EU5 countries by 2025. Also there are many industry players investing on development of NASH therapeutic drugs, and most of them are in phase II or III of clinical trials. Their requirement of non-invasive diagnostic tools for monitoring their drug effectiveness is expected to drive the growth for NASH biomarkers market over the forecasted period. Biomarkers based NASH diagnostic tests are proposed to be at lower cost and non-invasive which is expected to make them a preferred tool for NASH diagnosis over invasive liver biopsy and costly imaging techniques. Ongoing research in discovery and development of novel NASH biomarkers is expected to drive the growth of NASH biomarkers market. However presently available NASH biomarkers are less accurate and have little efficacy which makes their usage limited. Also their results are overlapping with other metabolic disorders which is anticipated to restrain the growth of NASH biomarkers market.

Global Non-alcoholic Steatohepatitis Biomarker Market: Segmentation

Based on the marker type the global non-alcoholic steatohepatitis biomarkers market is segmented in to five segments viz. serum biomarkers, hepatic fibrosis biomarkers, apoptosis biomarkers, oxidative stress biomarkers, and others. Serum biomarkers are expected to dominate the global NASH biomarkers market in the first half of the forecasted period. Owing to their indirect relation with NASH and other limitations they are expected to lose their market share in the second half of forecasted period. The Hepatic fibrosis markers are expected to grow exponentially over the forecasted period owing to their more accuracy and efficacy. This marker type segment is expected to hold the largest share of NASH biomarkers market by 2024. With expected launch of new diagnostic tools by Genfit SA and Exalenz Biosciences Ltd. the other markers segment is expected to have an exponential growth over the forecasted period.

Based on end-user, the global non-alcoholic steatohepatitis biomarkers market has been segmented into contract research organization (CRO) & pharmaceutical industry, academic research institutes, hospitals, and diagnostic laboratories. Owing to the requirement of non-invasive diagnostic tools for routine monitoring of drug therapy effectiveness during the clinical trial of drug candidates, the CRO & pharmaceutical industry end-user segment is expected to have a moderate growth over the forecasted period. However towards the end of forecasted period this segment is expected to be superseded by hospital and diagnostic laboratories end-user segment. With expected launch of companion diagnostic tests along with NASH therapeutic drugs the hospitals and diagnostic laboratories segments of end-user are expected to witness an exponential growth over forecasted period. The hospital end-user segment is expected to grow at CAGR of 36.6% while diagnostic laboratories segment is expected to grow at CAGR of 37.0% over the forecasted period.

Global Non-alcoholic Steatohepatitis Biomarker Market: Regional Outlook

Geographically, the non-alcoholic steatohepatitis biomarkers market has been segmented into five regions: North America, Latin America, Europe, Asia Pacific and Middle East and Africa. These regions have been further segmented by marker type and end-user segments. The competition matrix section included in the report is likely to assist the existing players to increase their market shares and new companies to establish their presence in the global non-alcoholic steatohepatitis biomarkers market.

Key Players Mentioned in this Report are:

The report also profiles major players in the market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include One Way Liver S.L., BioPredictive S.A.S, Siemens Heathcare Pvt. Ltd. (now Siemens Healthineers), Genfit SA, Exalenz Biosciences Ltd., Quest Diagnostic Incorporated, Prometheus Laboratories Corp. (part of Nestle Health Sciences) and SNIBE diagnostics.

The global non-alcoholic steatohepatitis biomarkers market has been segmented as follows:

Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market, by Marker Type

  • Serum Biomarkers
  • Hepatic Fibrosis Biomarkers
  • Apoptosis Biomarkers
  • Oxidative Stress Biomarkers
  • Others

Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market, by End-User

  • Contract Research Organization(CRO) & Pharmaceutical Industry
  • Academic Research Institutes
  • Hospitals
  • Diagnostic Laboratories

Table of Content

Chapter 1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

Chapter 2. Assumptions and Research Methodology

Chapter 3. Executive Summary: Global Nonalcoholic Steatohepatitis (NASH) Biomarkers Market 

Chapter 4. Market Overview
4.1. Introduction
4.1.1. Marker Type Definition
4.1.2. Industry Evolution / Developments
4.2. Market Overview
4.3. Key Market Indicators
4.4. Market Dynamics
4.4.1. Drivers
4.4.2. Restraints
4.4.3. Opportunities
4.4.4. Trends
4.5. Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Analysis and Forecast, 2016 – 2024
4.5.1. Pricing – Actuals and Projections, 2016-2024 (US$)
4.5.2. Market Revenue Projections (US$ Mn)
4.6. Porter’s Five Force Analysis
4.7. Value Chain Analysis
4.8. Market Outlook

Chapter 5. Global Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Analysis and Forecasts, By Marker Type
5.1. Introduction & Definition
5.2. Key Trends
5.3. Comparison Matrix
5.4. Market Size (US$ Mn) Forecast By Marker Type
5.4.1. Serum Biomarkers
5.4.2. Hepatic Fibrosis Markers
5.4.3. Oxidative Stress Markers
5.4.4. Apoptosis Markers
5.4.5. Others (miRNA, carbon isotopes)
5.5. Market Attractiveness By Marker Type  

Chapter 6. Global Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Analysis and Forecasts, By End User
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Key Trends
6.4. Comparison Matrix
6.5. Market Size (US$ Mn) Forecast By End User
6.5.1. Contract Research Organizations / pharmaceutical industry
6.5.2. Academic Research Institute
6.5.3. Hospitals
6.5.4. Diagnostic Laboratories
6.6. Market Attractiveness By End User  

Chapter 7. Global Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Analysis and Forecasts, By Region
7.1. Key Findings
7.2. Key Trends
7.3. Market Size (US$ Mn) Forecast By Region
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific 
7.3.5. Middle East and Africa
7.4. Market Attractiveness By Region

Chapter 8. North America Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Analysis and Forecast
8.1. Introduction
8.2. Key Findings / Developments
8.3. Key Trends
8.4. Market Size (US$ Mn) Forecast By Marker Type
8.4.1. Serum Biomarkers
8.4.2. Hepatic Fibrosis Markers
8.4.3. Oxidative Stress Markers
8.4.4. Apoptosis Markers
8.4.5. Others (miRNA, carbon isotopes)
8.5. Market Size (US$ Mn) Forecast By End User
8.5.1. Contract Research Organizations / pharmaceutical industry
8.5.2. Academic Research Institute
8.5.3. Hospitals
8.5.4. Diagnostic Laboratories
8.6. Market Size (US$ Mn) Forecast, By Country
8.6.1. U.S.
8.6.2. Canada
8.7. Market Attractiveness Analysis 
8.7.1. By Marker Type
8.7.2. By End User
8.7.3. By Country

Chapter 9. Europe Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Analysis and Forecast
9.1. Introduction
9.2. Key Findings / Developments
9.3. Key Trends
9.4. Market Size (US$ Mn) Forecast By Marker Type
9.4.1. Serum Biomarkers
9.4.2. Hepatic Fibrosis Markers
9.4.3. Oxidative Stress Markers
9.4.4. Apoptosis Markers
9.4.5. Others (miRNA, carbon isotopes)
9.5. Market Size (US$ Mn) Forecast By End User
9.5.1. Contract Research Organizations / pharmaceutical industry
9.5.2. Academic Research Institute
9.5.3. Hospitals
9.5.4. Diagnostic Laboratories
9.6. Market Size (US$ Mn) Forecast, By Country
9.6.1. U.K.
9.6.2. France
9.6.3. Germany
9.6.4. Spain
9.6.5. Rest of Europe
9.7. Market Attractiveness Analysis 
9.7.1. By Marker Type
9.7.2. By End User
9.7.3. By Country 

Chapter 10. Asia Pacific Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings / Developments
10.3. Key Trends
10.4. Market Size (US$ Mn) Forecast By Marker Type
10.4.1. Serum Biomarkers
10.4.2. Hepatic Fibrosis Markers
10.4.3. Oxidative Stress Markers
10.4.4. Apoptosis Markers
10.4.5. Others (miRNA, carbon isotopes)
10.5. Market Size (US$ Mn) Forecast By End User
10.5.1. Contract Research Organizations / pharmaceutical industry
10.5.2. Academic Research Institute
10.5.3. Hospitals
10.5.4. Diagnostic Laboratories
10.6. Market Size (US$ Mn) Forecast, By Country
10.6.1. Japan
10.6.2. China
10.6.3. India
10.6.4. Rest of APAC
10.7. Market Attractiveness Analysis 
10.7.1. By Marker Type
10.7.2. By End User
10.7.3. By Country 

Chapter 11. Latin America Nonalcoholic Steatohepatitis (NASH) Biomarkers Market  Analysis and Forecast
11.1. Introduction
11.2. Key Findings / Developments
11.3. Key Trends
11.4. Market Size (US$ Mn) Forecast By Marker Type
11.4.1. Serum Biomarkers
11.4.2. Hepatic Fibrosis Markers
11.4.3. Oxidative Stress Markers
11.4.4. Apoptosis Markers
11.4.5. Others (miRNA, carbon isotopes)
11.5. Market Size (US$ Mn) Forecast By End User
11.5.1. Contract Research Organizations / pharmaceutical industry
11.5.2. Academic Research Institute
11.5.3. Hospitals
11.5.4. Diagnostic Laboratories
11.6. Market Size (US$ Mn) Forecast, By Country
11.6.1. Brazil
11.6.2. Mexico
11.6.3. Argentina
11.6.4. Rest of Latin America
11.7. Market Attractiveness Analysis 
11.7.1. By Marker Type
11.7.2. By End User
11.7.3. By Country 

Chapter 12. Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Biomarkers Market  Analysis and Forecast
12.1. Introduction
12.2. Key Findings / Developments
12.3. Key Trends
12.4. Market Size (US$ Mn) Forecast By Marker Type
12.4.1. Serum Biomarkers
12.4.2. Hepatic Fibrosis Markers
12.4.3. Oxidative Stress Markers
12.4.4. Apoptosis Markers
12.4.5. Others (miRNA, carbon isotopes)
12.5. Market Size (US$ Mn) Forecast By End User
12.5.1. Contract Research Organizations / pharmaceutical industry
12.5.2. Academic Research Institute
12.5.3. Hospitals
12.5.4. Diagnostic Laboratories
12.6. Market Size (US$ Mn) Forecast, By Country
12.6.1. South Africa
12.6.2. GCC Countries
12.6.3. Rest of MEA
12.7. Market Attractiveness Analysis 
12.7.1. By Marker Type
12.7.2. By End User
12.7.3. By Country 

Chapter 13. Competition Landscape
13.1. Nonalcoholic Steatohepatitis (NASH) Biomarkers Market – Competition Matrix (By Tier and Size of companies) (2015)
13.2. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
13.2.1. BioPredictive S.A.S
13.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.1.2. Product Portfolio
13.2.1.3. SWOT Analysis
13.2.1.4. Strategic Overview
13.2.2. One Way Liver S.L.
13.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.2.2. Product Portfolio
13.2.2.3. SWOT Analysis
13.2.2.4. Strategic Overview
13.2.3. Genfit SA
13.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.3.2. Product Portfolio
13.2.3.3. SWOT Analysis
13.2.3.4. Financial Overview
13.2.3.5. Strategic Overview
13.2.4. Quest Diagnostics Incorporated
13.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.4.2. Product Portfolio
13.2.4.3. SWOT Analysis
13.2.4.4. Financial Overview
13.2.4.5. Strategic Overview
13.2.5. Prometheus Laboratories Inc. (Part of Nestle Health Sciences)
13.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.5.2. Product Portfolio
13.2.5.3. SWOT Analysis
13.2.5.4. Financial Overview
13.2.5.5. Strategic Overview
13.2.6. Siemens Healthcare Private Ltd. (now Siemens Healthineers)
13.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.6.2. Product Portfolio
13.2.6.3. SWOT Analysis
13.2.6.4. Financial Overview
13.2.6.5. Strategic Overview
13.2.7. Shenzhen New Industries Biomedical Engineering Co. Ltd. (SNIBE Diagnostics)
13.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.7.2. Product Portfolio
13.2.7.3. SWOT Analysis
13.2.7.4. Financial Overview
13.2.7.5. Strategic Overview
13.2.8. Exalenz Biosciences Ltd.
13.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.8.2. Product Portfolio
13.2.8.3. SWOT Analysis
13.2.8.4. Financial Overview
13.2.8.5. Strategic Overview

Chapter 14. Key Take Away

List of Table

Table 01: Global Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast, by Marker Type, 2015–2024
Table 02: Global Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast, by End-user, 2015–2024
Table 03: Global Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast, by Region,
Table 04: North America Nonalcoholic Steatohepatitis Market Size (US$ Mn) Forecast, by Marker Type, 2015–2024
Table 05: North America Nonalcoholic Steatohepatitis Market Size (US$ Mn) Forecast, by End User, 2015–2024
Table 06: North America Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast, by Country,
Table 07: Europe Nonalcoholic Steatohepatitis Market Size (US$ Mn) Forecast, by Marker Type, 2015–2024
Table 08: Europe Nonalcoholic Steatohepatitis Market Size (US$ Mn) Forecast, by End User, 2015–2024
Table 09: Europe Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast, by Country, 2015–2024
Table 10: Asia Pacific Nonalcoholic Steatohepatitis Market Size (US$ Mn) Forecast, by Marker Type, 2015–2024
Table 11: Asia Pacific Nonalcoholic Steatohepatitis Market Size (US$ Mn) Forecast, by End User, 2015–2024
Table 12: Asia Pacific Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast, by Country, 2015–2024
Table 13: Latin America Nonalcoholic Steatohepatitis Market Size (US$ Mn) Forecast, by Marker Type, 2015–2024
Table 14: Latin America Nonalcoholic Steatohepatitis Market Size (US$ Mn) Forecast, by End User, 2015–2024
Table 15: Latin America Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast, by Country, 2015–2024
Table 16: Middle East and Africa Nonalcoholic Steatohepatitis Market Size (US$ Mn) Forecast, by Marker Type, 
Table 17: Middle East and Africa Nonalcoholic Steatohepatitis Market Size (US$ Mn) Forecast, by End User, 2015–2024
Table 18: Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast, by Country, 2015–2024

List of Chart

Figure 01: Global Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2014–2024
Figure 02: Global Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, by Market Type, 2017 and 2024
Figure 03: Global Serum Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2024
Figure 04: Global Hepatic Fibrosis Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015-2024
Figure 05: Global Apoptosis Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2024
Figure 06: Global Oxidative Stress Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2024
Figure 07: Global other Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2024
Figure 08: Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis, by Marker Type
Figure 09: Global Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, by End-user, 2017 and 2024
Figure 10: Global CRO / Pharmaceutical Industry Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2024
Figure 11: Global Academic Research Institute Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2024
Figure 12: Global Hospital Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2024
Figure 13: Global Diagnostic Laboratories Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2024
Figure 14: Global Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis, by End-user
Figure 15: Global Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, by Region, 2017 and 2024 
Figure 16: Global Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis, by Region
Figure 17: North America Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, by Marker Type, 2017 and2024
Figure 18: North America Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, by End User, 2017 and 2024
Figure 19: North America Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2016–2024
Figure 20: North America Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis, by Country
Figure 21: North America Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, by Country, 2017 and 2024
Figure 22: North America Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis, by Marker Type
Figure 23: North America Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis, by End User
Figure 24: Europe Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, by Marker Type, 2017 and 2024
Figure 25: Europe Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, by End User, 2017 and 2024
Figure 26: Europe Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2016–2024
Figure 27: Europe Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis, by Country
Figure 28: Europe Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, by Country, 2017 and 2024
Figure 29: Europe Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis, by Marker Type
Figure 30: Europe Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis, by End User
Figure 31: Asia Pacific Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, by Marker Type, 2017 and 2024 
Figure 32: Asia Pacific Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, by End User, 2017 and 2024
Figure 33: Asia Pacific Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2016–2024
Figure 34: Asia Pacific Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis, by Country
Figure 35: Asia Pacific Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, by Country, 2017 and 2024
Figure 36: Asia Pacific Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis, by Marker Type
Figure 37: Asia Pacific Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis, by End User
Figure 38: Latin America Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, by Marker Type, 2017 and2024
Figure 39: Latin America Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, by End User, 2017 and 2024
Figure 40: Latin America Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2016–2024
Figure 41: Latin America Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis, by Country
Figure 42: Latin America Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, by Country, 2017 and 2024
Figure 43: Latin America Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis, by Marker Type
Figure 44: Latin America Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis, by End User
Figure 45: Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, by Marker Type, 2017 and 2024
Figure 46: Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, by End User, 2017 and 2024
Figure 47: Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2016–2024 
Figure 48: Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis, by Country
Figure 49: MEA Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, by Country, 2017 and 2024
Figure 50: MEA Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis, by Marker Type
Figure 51: MEA Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis, by End User

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *